18F-DCFPyL PET/CT guidelines
Copyright © 2023 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved..
The objective of this guide is to provide to nuclear medicine physicians a tool based on scientific evidence and prepared by consensus of experts, to perform the 18F-DCFPyL PET/CT procedure with safely and efficiently for patients with prostate cancer who present PSMA overexpression. For them, some recommendations will be established for 18F-DCFPyL PET/CT examination: reconstruction parameters, presentation of the images and their interpretation. The possible false positives of the procedure will be analysed, how to interpret them and how to avoid them. Finally, all exploration should lead to the preparation of a report that answers the clinician's question. For this, it is recommended to prepare a structured report that includes the PROMISE criteria as well as the classification of the findings according to PSMA-RADS parameters.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Revista espanola de medicina nuclear e imagen molecular - 42(2023), 3 vom: 07. Mai, Seite 203-208 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gutiérrez Cardo, A L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8W8T17847W |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 08.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.remnie.2023.02.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353841382 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353841382 | ||
| 003 | DE-627 | ||
| 005 | 20231226060934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.remnie.2023.02.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353841382 | ||
| 035 | |a (NLM)36878314 | ||
| 035 | |a (PII)S2253-8089(23)00026-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gutiérrez Cardo, A L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18F-DCFPyL PET/CT guidelines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a The objective of this guide is to provide to nuclear medicine physicians a tool based on scientific evidence and prepared by consensus of experts, to perform the 18F-DCFPyL PET/CT procedure with safely and efficiently for patients with prostate cancer who present PSMA overexpression. For them, some recommendations will be established for 18F-DCFPyL PET/CT examination: reconstruction parameters, presentation of the images and their interpretation. The possible false positives of the procedure will be analysed, how to interpret them and how to avoid them. Finally, all exploration should lead to the preparation of a report that answers the clinician's question. For this, it is recommended to prepare a structured report that includes the PROMISE criteria as well as the classification of the findings according to PSMA-RADS parameters | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cáncer de próstata | |
| 650 | 4 | |a DCFPyL | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Guía | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a PET/TC | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Lysine |2 NLM | |
| 650 | 7 | |a K3Z4F929H6 |2 NLM | |
| 650 | 7 | |a Urea |2 NLM | |
| 650 | 7 | |a 8W8T17847W |2 NLM | |
| 700 | 1 | |a Vallejo Casas, J A |e verfasserin |4 aut | |
| 700 | 1 | |a García Garzón, J R |e verfasserin |4 aut | |
| 700 | 1 | |a Tirado Hospital, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Medina López, R |e verfasserin |4 aut | |
| 700 | 1 | |a Freire Macías, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Fernández, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de medicina nuclear e imagen molecular |d 2018 |g 42(2023), 3 vom: 07. Mai, Seite 203-208 |w (DE-627)NLM26953881X |x 2253-8089 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:3 |g day:07 |g month:05 |g pages:203-208 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.remnie.2023.02.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 3 |b 07 |c 05 |h 203-208 | ||